Antiblood-clot pill could cut heart problems, study says

"Results from a mid-stage clinical trial released Monday involving a new type of pill designed to keep blood clots from forming suggests the treatment has the potential to prevent additional heart problems in people who've suffered a heart attack. Results from the phase 2 study looked at rivaroxaban, a drug from Bayer AG's health-care unit and Johnson & Johnson, in patients with so-called acute coronary syndrome - when a blood clot blocks a coronary artery, often leading to a heart attack. The study, which was led by C. Michael Gibson, the chief of cardiovascular research at Beth Israel Deaconess Medical Center in Boston, also showed patients had a risk of bleeding that increased with higher doses of rivaroxaban, a common problem with drugs designed to keep blood clots from forming" - WSJ